Having validated L1000, we set out to expand on the CMap pilot dataset in several dimensions. First, we increased the small molecule perturbations from 164 drugs to 19,811 small molecule drugs, tool compounds and screening library compounds including those with clinical utility, known mechanism of action, or nomination from the NIH Molecular Libraries Program. Each compound was profiled in triplicate, either at 6 or 24 hours following treatment.
